ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow.

Details of the presentations are as follows:
C1-Inhibitor Deficiency and Angioedema Workshop, Budapest, May 29-June 1, 2025.

  • Title: Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples
    Presenter: Evangelia Pardali, Ph.D.
    Format: Oral Presentation, O-02
    Date, time: Friday, May 30, 8:45-9:00 CEST (2:45-3:00 a.m. ET)
  • Title: Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
    Presenter: Markus Magerl, M.D.
    Format: Poster Presentation, P-19
    Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers
    Presenter: Zhi-Yi Zhang, Ph.D.
    Format: Poster Presentation, P-20
    Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Poster Presentation, P-17
    Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Oral Presentation, O-33
    Date, time: Saturday, May 31, 15:30-15:45 CEST (9:30-9:45 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Oral Presentation, O-34
    Date, time: Saturday, May 31, 15:45-16:00 CEST (9:45-10:00 a.m. ET)
  • Title: Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
    Presenter: Anna Valerieva, M.D., Ph.D.
    Format: Poster Presentation, P-56
    Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
  • Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Poster Presentation, P-42
    Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
  • Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
    Presenter: Ramón Lleonart, M.D.
    Format: Poster Presentation, P-55
    Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)
  • Title: Epidemiology of Bradykinin-Mediated Angioedema in the European Population
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation, P-30
    Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)

2025 Eastern Allergy Conference, Palm Beach, Fl., May 29-June 1, 2025.

  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: John Anderson, M.D.
    Format: Poster Presentation
    Date, time: Friday, May 30, 9:45-11:00 a.m. ET
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: John Anderson, M.D.
    Format: Poster Presentation
    Date, time: Friday, May 30, 9:45-11:00 a.m. ET

EAACI Congress 2025, Glasgow, June 13-16, 2025.

  • Title: Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema
    Presenter: Evangelia Pardali, Ph.D.
    Format: Flash Talk (e-Poster), Abstract #000949, FT03
    Date, time: Friday, June 13, 13:15-14:45 BST (8:15-9:45 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Thematic Poster Session (e-Poster and Poster Session) Abstract #000070
    Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: Henriette Farkas, M.D., Ph.D., D.Sc.
    Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000069
    Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
  • Title: Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000331
    Date, time: Sunday, June 15, 12:45-13:45 BST (7:45-8:45 a.m. ET)
  • Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
    Presenter: Anna Valerieva, M.D., Ph.D.
    Format: Flash Talk (e-Poster), Abstract #000076, FT16
    Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
  • Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    Presenter: William Lumry, M.D.
    Format: Flash Talk (e-Poster), Abstract #000068, FT16
    Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
  • Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study
    Presenter: Markus Magerl, M.D.
    Format: Flash Talk (e-Poster), Abstract #000075, FT16
    Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
  • Title: Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone
    Presenter: Laurence Bouillet, M.D., Ph.D.
    Format: Oral Presentation, Abstract #000044, OAS18
    Date, time: Sunday, June 15, 15:45-17:15 BST (10:45 a.m.-12:15 p.m. ET)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.


Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.